{
    "clinical_study": {
        "@rank": "60475", 
        "arm_group": {
            "arm_group_label": "Phosphorus Supplement", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Patients with Dent disease have suppressed levels of FGF 23 which contributes to\n      hypercalciuria, kidney stones, nephrocalcinosis and renal failure.  Supplementation with\n      phosphorus may reduce hypercalciuria."
        }, 
        "brief_title": "Role Of Phosphorus And FGF 23 In Patients With Dent Disease", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Dent Disease", 
        "condition_browse": {
            "mesh_term": "Dent Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients will be recruited from those in the RKSC Dent Registry\n\n             Diagnostic criteria for Dent disease include:\n\n             A. 1. LMWP (at least 5 times above the upper limit of normal) and at least 1 of the\n             following criteria: 1. Hypercalciuria, 2. Kidney stones, 3. Nephrocalcinosis, 4.\n             Hypophosphatemia, 5. Renal phosphate leak, 6. Aminoaciduria, 7. Glucosuria without\n             diabetes mellitus, 8. Hematuria, 9. Renal insufficiency, 10. Family history with\n             x-linked inheritance or B. 1 of the above criteria (1-9) and confirmed genetic\n             mutation of CLCN5 or OCRL1.\n\n          2. Idiopathic calcium nephrolithiasis with renal phosphate leak\n\n               1. Male patients > 18 years old\n\n               2. History of symptomatic calcium oxalate or calcium phosphate stone,\n                  hypercalciuria (>250 mg/24 hrs), renal phosphate leak (TMP/GFR <2.07 mg/dl)\n\n          3. Idiopathic calcium nephrolithiasis without renal phosphate leak\n\n               1. Male patients > 18 years old\n\n               2. History of symptomatic calcium oxalate or calcium phosphate stone,\n                  hypercalciuria (>250 mg/24 hrs), renal phosphate leak (TMP/GFR <2.07 mg/dl)\n\n        Exclusion Criteria:\n\n          1. Exclusion for Dent disease include: primary or secondary hyperparathyroidism,\n             hyperthyroidism, chronic diarrhea states; intake of thiazide diuretics,\n             glucocorticoids, or estrogens within one month of the study.\n\n          2. Exclusion criteria for calcium stone formers include: primary or secondary\n             hyperparathyroidism, hyperthyroidism, estimated GFR <40 ml/mn/1.73m2, chronic\n             diarrhea states; intake of thiazide diuretics, glucocorticoids, or estrogens within\n             one month of the study.\n\n          3. Exclusion criteria include history of symptomatic or asymptomatic kidney stone\n             disease; primary or secondary hyperparathyroidism; estimated GFR <40 ml/min/1.73m2,\n             chronic diarrhea states; intake of thiazide diuretics, glucocorticoids, or estrogens\n             within one month of the study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02016235", 
            "org_study_id": "13-004774"
        }, 
        "intervention": {
            "arm_group_label": "Phosphorus Supplement", 
            "intervention_name": "Phosphorus Supplement", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Dent", 
            "Dents", 
            "Dent Disease", 
            "Phosphorus Supplements", 
            "FGF 23"
        ], 
        "lastchanged_date": "December 13, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Barbara Siede"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rarekidneystones@mayo.edu", 
                    "last_name": "Barbara M Seide", 
                    "phone": "800-270-4637"
                }, 
                "contact_backup": {
                    "email": "rarekidneystones@mayo.edu", 
                    "last_name": "Alicia M Meek", 
                    "phone": "800-270-4637"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Role Of Phosphorus And FGF 23 In Patients With Dent Disease", 
        "overall_contact": {
            "email": "rarekidneystones@mayo.edu", 
            "last_name": "Barbara M Seide", 
            "phone": "800-270-4637"
        }, 
        "overall_contact_backup": {
            "email": "rarekidneystones@mayo.edu", 
            "last_name": "Alicia M Meek", 
            "phone": "800-270-4637"
        }, 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "John C Lieske, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This study will measure the changes in a 24 hr urine supersaturation and serum after phosphorus is taken for two weeks to decrease stone formation", 
            "measure": "Change in 24 hr urine and serum after 2 weeks of phosphorus supplementation", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02016235"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "John Lieske", 
            "investigator_title": "M.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}